Mocetinostat (MGCD0103)

Catalog No.S1122 Synonyms: MG0103

Mocetinostat (MGCD0103) Chemical Structure

Molecular Weight(MW): 396.44

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS0PEBp NVLHZXRKUUN3ME2zMlA1KM7:TR?= NVnJS|RHOjZ|N{iwN|g>
BT549 M1:xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vSOlQ5KGh? NHnvXpJKSzVyPUSuN|gh|ryP M4Hpd|I3Ozd6MEO4
MCF7 M3y0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLvVoI1QCCq MlLtTWM2OD1yLk[3JO69VQ>? NGXmT|kzPjN5OECzPC=>
T47D Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe4dW41QCCq MlfkTWM2OD1zLkG3JO69VQ>? NGi3[mIzPjN5OECzPC=>
MOLP8 NXXZW5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy0PEBp MVTJR|UxRTBwNtMxJFAvODUQvF2= NWrPdnN7OjZyOUG1NVg>
Panc1 NE\ldW5HfW6ldHnvckBCe3OjeR?= MmTFNE42NzFxMj61JO69VQ>? NWnOc3B{PDhiaB?= MUPEUXNQ NUK4flVofXC{ZXf1cIF1\XNibXnSMVIxOw>? MnHTNlU5PzJ7NEG=
Panc1 MmTnSpVv[3Srb36gRZN{[Xl? Mn\zNE42NzFxMj61JO69VQ>? MUS0PEBp MUDEUXNQ NVTQcHR4emWmdXPld{BmgHC{ZYPzbY9vKG:oIGrFRlEhd25iYn;0bEBuWk6DIHHu[EBxem:2ZXnuJIxmfmWuwrC= Mmf4NlU5PzJ7NEG=
Panc1 NEjMUIdCeG:ydH;zbZMhSXO|YYm= MV[xxsDPxE1? MkX6O|LDqGh? MkHaSG1UVw>? NUThSmNGe2Wwc3n0bZpmeyCSYX7jNUBk\WyuczDmc5Ih\2WvY3n0ZYJqdmVvaX7keYNm\CCjcH;weI9{cXN? M4f3N|I2QDd{OUSx
Panc1 M3;GUGNmdGxiVnnhZoltcXS7IFHzd4F6 M1TkO|HDqM7:TR?= MUO3NuKhcA>? MlPBSG1UVw>? M1zxVIVvcGGwY3XzJIdmdWOrdHHibY5mNWmwZIXj[ZMh[2WubDD2bYFjcWyrdImg[IVkemWjc3W= M3TY[VI2QDd{OUSx
MMCs MnjVSpVv[3Srb36gRZN{[Xl? NVXiS|BpOSEQvH2= MXWwMVQ5KGh? NX\YemlocW6lcnXhd4V{KE6SUlGgdJJwfGWrbjDlfJBz\XO|aX;uxsAzNjgkgKOzMlUh\m:uZB?= NUjnW4Z6OjR2NUGzO|g>
MMCs NGO3W3NHfW6ldHnvckBCe3OjeR?= NWDhVpd2OC53L{Gg{txO NEnvNIszPCCq NEPzXIp{cG:5czC0OU1nd2ymIIP0bY12dGG2aX;uJIlvKGOJTWCgcIV3\Wy| MoPRNlQ1PTF|N{i=
MMCs NFPoTWNHfW6ldHnvckBCe3OjeR?= MWCxxsDPxE1? M2rrVVI1KGh? MnvqbY5kemWjc3XzJGhCXCCjY4Tpeol1gQ>? MlLmNlQ1PTF|N{i=
MMCs M1v6V2Z2dmO2aX;uJGF{e2G7 NUm2dY12OcLizszN M{\j[FI1KGh? NYXGfHFn[XWpbXXueJMh\2yxYnHsJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iCqaYP0c45mKEh|LVu5M|E1KCiKMz3LPU8yPGGlKTDhcoQhUDRvS{GyJEhJPC2NMULhZ{k> M4\O[|I1PDVzM{e4
MMCs MYfGeY5kfGmxbjDBd5NigQ>? NYe3epY3OcLizszN MlnrOk0zPCCq M1zmcIRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdIOgeIhmKHS{aX3leIh6dGG2aX;uJIxmfmWuIH;mJGg{NUt7IDjIN{1MQW2nMzm= MnSzNlQ1PTF|N{i=
BxPC-3 NEL5VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnlSWM2OD1zLkGg{txO NXnQfYxIOjF|N{W2O|k>
AsPC-1 M{L5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrFR|UxRTNwOTFOwG0> NUm2fpdTOjF|N{W2O|k>
MiaPaca-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfmSWM2OD1yLk[g{txO NVm3WWg2OjF|N{W2O|k>
Panc-1 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;FR|UxRTFwODFOwG0> M1mwflIyOzd3Nke5
PAXF 546L† NGnj[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\FR|UxRTFwNTFOwG0> NV73eJFsOjF|N{W2O|k>
PAXF 1657L† MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X0WWVEPTB;MD6zJO69VQ>? MmrCNlE{PzV4N{m=
HCT15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P3UWlEPTB;MD63JO69VQ>? M3XwUVIyOzF5NEW1
HT-29 NVPmdXdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYVHNZUUN3ME2wMlch|ryP NULU[oREOjF|MUe0OVU>
SW48 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwODFOwG0> NWOwblVVOjF|MUe0OVU>
SW620 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fIemlEPTB;MTFOwG0> Mm\WNlE{OTd2NUW=
HMEC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XJTmlEPTB;MUmg{txO M2\afFIyOzF5NEW1
ANBL6  NEHPUWhHfW6ldHnvckBCe3OjeR?= MUKxxsDPxE1? M4fL[|I1KGh? MYrlcohidmOnczC1MWFENWmwZIXj[YQhVUGJRT3BN{Bo\W6nIHX4dJJme3Orb36= MXGyNVE4OTh{MR?=
LP1 NXzMcnN{TnWwY4Tpc44hSXO|YYm= MV[xxsDPxE1? MkXCNlQhcA>? Mmnx[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO|aX;u MYeyNVE4OTh{MR?=
HD-LM2 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHDOZk4OsLiaB?= MY\EUXNQ MkDyTWM2OD1zLki4JO69VQ>? Mn;TNlA5QDBzMEe=
L428 NYDYbFQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzSXdGPzMEoHi= M1\YeWROW09? MlWxTWM2OD1zLkm2JO69VQ>? NVm1SmNoOjB6OECxNFc>
KM-H2 NWq2[VlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorNO|LDqGh? M{jhTmROW09? MWjJR|UxRTJwOE[g{txO M3HBOFIxQDhyMUC3
HD-LM2 MVjGeY5kfGmxbjDBd5NigQ>? M3XJclAvOS1{IN88US=> NE[xR3czPCCqwrC= MV\EUXNQ NEDWO3d{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx NXPz[GFkOjB6OECxNFc>
L428 MXnGeY5kfGmxbjDBd5NigQ>? NIHx[5cxNjFvMjFOwG0> NY\HdopxOjRiaNMg NX\zbplITE2VTx?= MY\zbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz M3;qUFIxQDhyMUC3
KM-H2 MlHLSpVv[3Srb36gRZN{[Xl? M4mwSVAvOS1{IN88US=> NF3sNmYzPCCqwrC= MVTEUXNQ NYjEfmtxe2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=> MUOyNFg5ODFyNx?=
HD-LM2 NFrDVGhCeG:ydH;zbZMhSXO|YYm= NI\DUIcxNjFxMD61M|Eh|ryP M1ixOFQ5KGh? NHfpbmZFVVOR M2HWXIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MlS2NlA5QDBzMEe=
L428 M{X0O2Fxd3C2b4Ppd{BCe3OjeR?= MY[wMlEwOC53L{Gg{txO M{\OclQ5KGh? M{DVXmROW09? M1LaNolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NVjZSYE2OjB6OECxNFc>
KM-H2 M{H4XGFxd3C2b4Ppd{BCe3OjeR?= NFL1RXcxNjFxMD61M|Eh|ryP Ml\LOFghcA>? NYD3[3hjTE2VTx?= NGjxRYxqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NFHOTG4zODh6MEGwOy=>
HD-LM2 MXrGeY5kfGmxbjDBd5NigQ>? NWHmcYdKOcLizszN NYnnN5hvOjRxNEigbC=> M3Had2ROW09? NF[wXFRld3ewcnXneYxifGW|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{ MlnoNlA5QDBzMEe=
L428 NX7MU5A{TnWwY4Tpc44hSXO|YYm= M3;BeFHDqM7:TR?= NYTjdpV6OjRxNEigbC=> M3\zdWROW09? NVXIe5pZ\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? Mn\ZNlA5QDBzMEe=
KM-H2 M2nQRWZ2dmO2aX;uJGF{e2G7 MoTrNeKh|ryP MkjVNlQwPDhiaB?= MmK3SG1UVw>? MY\kc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz MYWyNFg5ODFyNx?=
HD-LM2 MljwSpVv[3Srb36gRZN{[Xl? Mn;QNE42NzFizszN MV:yOE81QCCq NXu3U3VYTE2VTx?= MmCyeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NFfoRXYzODh6MEGwOy=>
L428 MnzNSpVv[3Srb36gRZN{[Xl? NV7BNolROC53L{Gg{txO M1\DflI1NzR6IHi= MlS5SG1UVw>? MnTGeZBz\We3bHH0[ZMhXE6ILd8xJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= M1TJUFIxQDhyMUC3
KM-H2 M{G1UGZ2dmO2aX;uJGF{e2G7 NFfDPGYxNjVxMTFOwG0> MXqyOE81QCCq NYnsWZBCTE2VTx?= M1nvRZVxemWpdXzheIV{KFSQRj5OtUBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M2[yb|IxQDhyMUC3
HD-LM2 NXLhb5JZTnWwY4Tpc44hSXO|YYm= M4DwU|HDqM7:TR?= NI[z[2MxNjJ3LUS4JIg> Mk[0SG1UVw>? Mmm4ZYN1cX[jdHXzJG5HNWuE NI\sTXczODh6MEGwOy=>
L428 NHnxNo1HfW6ldHnvckBCe3OjeR?= NYfWRmtNOcLizszN MojDNE4zPS12ODDo M2H1OGROW09? NIL1[4Ri[3SrdnH0[ZMhVkZva1K= NGX2[XozODh6MEGwOy=>
KM-H2 MXzGeY5kfGmxbjDBd5NigQ>? M3nGflHDqM7:TR?= M4PGdFAvOjVvNEigbC=> NFviW4dFVVOR MkjuZYN1cX[jdHXzJG5HNWuE NVu4U5lGOjB6OECxNFc>
H526 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO4WIMzUUN3ME20PFAhdk1? MmDSNlA3QDJ4NEO=
H146 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfvXWNuUUN3ME2zOUBvVQ>? NH3QS3gzODZ6Mk[0Ny=>
H82 M2CzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWThcWgyUUN3ME2yOVAhdk1? MX:yNFY5OjZ2Mx?=
DMS114 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\TW21oUUN3ME22OFAhdk1? NX7uPWVSOjB4OEK2OFM>
HeLa M4fRcWZ2dmO2aX;uJGF{e2G7 MY[wMlMuOTBizszN M3nSSlghcA>? NI[0OG1FVVOR MV\pcoNz\WG|ZYOgZYNmfHmuYYTl[EBJOyCNOTCoTFNMQUGlKTDheEAyOCEQvF2= NIXNSHAzODV|OEi0NC=>
HeLa MYXGeY5kfGmxbjDBd5NigQ>? MUOwMlMuOTBizszN MYm4JIg> MXTEUXNQ M2D2Zolv[3KnYYPld{Bk[XOyYYPlJFMh[W6mIEegZYN1cX[jdHnvckBld3OnIHTldIVv\GWwdHz5 M4LsUVIxPTN6OESw
HeLa NH3HXnNHfW6ldHnvckBCe3OjeR?= NXjnVpZ7OTBizszNxsA> NITKcJg3NzF{L{K0JIg> NVLodpN6TE2VTx?= NFPGcWNqdmS3Y3XzJI1qfG:2aXOgZYNkfW23bHH0bY9vKGGwZDDk[YxigWWmIICyNUBmgHC{ZYPzbY9v M{Xx[FIxPTN6OESw
HeLa  Mom5SpVv[3Srb36gRZN{[Xl? MWWxNEDPxE4EoB?= M2fm[FchcA>? MVvEUXNQ M13I[IRqe3K3cITzJI5wem2jbDDzdIlv\GynIHPo[YNseG:rboSg[pVv[3Srb36= NV7iR25iOjB3M{i4OFA>
PBMC  MnPDRZBweHSxc3nzJGF{e2G7 NInONmkxNjVxMj:zJO69VQ>? M2\jUVI1NzR6IHi= MWnpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MWeyNFQxPjl2Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-H3 / Ac-H4 / Ac-tubulin ; 

PubMed: 29186204     


Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.

Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; 

PubMed: 27551526     


(a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. 

29186204 27551526
Immunofluorescence
Nanog / MHC ; 

PubMed: 26240433     


c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.

E-cadherin / ZEB1 ; 

PubMed: 25872941     


Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.

26240433 25872941
Growth inhibition assay
Cell viability; 

PubMed: 26378038     


B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software. 

26378038
In vivo MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. [1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. [2]

Protocol

Kinase Assay:[1]
- Collapse

HDAC enzyme assay in vitro:

The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:[1]
- Collapse
  • Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
  • Concentrations: 0-60 μM
  • Incubation Time: 72 hours
  • Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO2. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing H1437 tumors
  • Formulation: PBS acidified with 0.1 M HCl or PEG400/0.2 M HCl saline, 40:60
  • Dosages: 80 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.44
Formula

C23H20N6O

CAS No. 726169-73-9
Storage powder
in solvent
Synonyms MG0103

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02993991 Withdrawn Drug: Mocetinostat|Biological: Durvalumab Squamous Cell Carcinoma Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network Toronto|Mirati Therapeutics Inc.|AstraZeneca October 10 2017 Phase 1
NCT02805660 Active not recruiting Drug: mocetinostat|Drug: durvalumab Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02236195 Completed Drug: Mocetinostat Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2
NCT00666497 Terminated Drug: Azacitidine|Drug: MGCD0103 Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) Mirati Therapeutics Inc. June 2008 Phase 2
NCT00511576 Terminated Drug: MGCD0103 & Docetaxel Breast Cancer|Lung Cancer|Pulmonary Cancer|Non-Small-Cell Lung Carcinoma|Prostate Cancer|Prostatic Cancer|Gastric Cancer|Stomach Cancer Mirati Therapeutics Inc. August 2007 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) supplier | purchase Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) cost | Mocetinostat (MGCD0103) manufacturer | order Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID